Hologic/$HOLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hologic
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Ticker
$HOLX
Sector
Primary listing
Employees
7,063
Headquarters
Website
Hologic Metrics
BasicAdvanced
$15B
27.75
$2.41
0.63
-
Price and volume
Market cap
$15B
Beta
0.63
52-week high
$82.66
52-week low
$51.90
Average daily volume
2M
Financial strength
Current ratio
3.555
Quick ratio
2.585
Long term debt to equity
51.812
Total debt to equity
51.812
Interest coverage (TTM)
7.92%
Profitability
EBITDA (TTM)
1,241.7
Gross margin (TTM)
60.86%
Net profit margin (TTM)
13.79%
Operating margin (TTM)
23.43%
Effective tax rate (TTM)
17.54%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
6.69%
Return on equity (TTM)
11.38%
Valuation
Price to earnings (TTM)
27.752
Price to revenue (TTM)
3.791
Price to book
3.1
Price to tangible book (TTM)
26.76
Price to free cash flow (TTM)
16.703
Free cash flow yield (TTM)
5.99%
Free cash flow per share (TTM)
4.011
Growth
Revenue change (TTM)
1.29%
Earnings per share change (TTM)
-17.18%
3-year revenue growth (CAGR)
-8.23%
10-year revenue growth (CAGR)
4.34%
3-year earnings per share growth (CAGR)
-25.85%
10-year earnings per share growth (CAGR)
17.89%
What the Analysts think about Hologic
Analyst ratings (Buy, Hold, Sell) for Hologic stock.
Bulls say / Bears say
Private equity firms Blackstone and TPG have renewed talks to take Hologic private at a $14.7 billion valuation (around $66 per share), signaling confidence in the company’s operational comeback and the value of its women’s health products, with negotiations referencing mid-single-digit annual revenue growth for fiscal 2026 driven by new product launches and efforts to offset tariffs.
In fiscal 2025's first quarter, Hologic’s diagnostics division—the company’s largest by revenue—posted $470.6 million in sales, topping the $461 million consensus and showing steady demand for molecular diagnostics tests.
In the third quarter of fiscal 2025, Hologic reported strong liquidity, with $343.2 million in operating cash flow and $1.88 billion in cash plus short-term investments. This supports a low adjusted net leverage ratio of 0.6 times, giving the company flexibility for investing in growth and buying back shares.
Hologic cut its fiscal 2025 revenue forecast to $4.05 billion–$4.10 billion due to weak sales in breast health products and continued saline shortages, causing the stock to fall 5 percent after hours.
The company reduced its adjusted profit outlook for fiscal 2025 to $4.15–$4.25 per share, citing tariff uncertainties and geopolitical factors—projecting a $20–$25 million headwind each quarter—which pushed margins lower and caused shares to dip 3 percent.
Hologic’s stock has dropped about 24 percent year-to-date amid U.S. tariffs on China and Costa Rica and slower mammography equipment demand, highlighting ongoing challenges in its core breast health business.
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Hologic Financial Performance
Revenues and expenses
Hologic Earnings Performance
Company profitability
Hologic News
AllArticlesVideos
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025
Business Wire2 weeks ago
Hologic Receives FDA Clearance and CE Mark for Automated Molecular Tests to Detect Common Causes of Infectious Gastroenteritis
Business Wire2 weeks ago
New Survey Results Underscore the Need to #BustTheMyth About Mammograms
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hologic stock?
Hologic (HOLX) has a market cap of $15B as of October 17, 2025.
What is the P/E ratio for Hologic stock?
The price to earnings (P/E) ratio for Hologic (HOLX) stock is 27.75 as of October 17, 2025.
Does Hologic stock pay dividends?
No, Hologic (HOLX) stock does not pay dividends to its shareholders as of October 17, 2025.
When is the next Hologic dividend payment date?
Hologic (HOLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Hologic?
Hologic (HOLX) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.